GoodRx(US:GDRX)2025-05-07 20:50Revenue Performance - Revenue increased by 3% to $203.0 million from $197.9 million[102] - Total revenue for Q1 2025 was $202.97 million, a 1.1% increase from $197.88 million in Q1 2024[120] - Prescription transactions revenue increased by $3.5 million, or 2%, year-over-year, totaling $148.92 million in Q1 2025[123] - Subscription revenue decreased by $1.6 million, or 7%, year-over-year, totaling $21.02 million in Q1 2025[124] - Pharma manufacturer solutions revenue increased by $4.1 million, or 17%, year-over-year, totaling $28.65 million in Q1 2025[125] Profitability - Net income was $11.1 million with a net income margin of 5.4%, compared to a net loss of $1.0 million and a net loss margin of 0.5% in the previous year[102] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024[122] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[122] - Adjusted EBITDA rose to $69.8 million, with an Adjusted EBITDA Margin of 34.4%, up from $62.8 million and 31.7% respectively[102] Consumer Metrics - Monthly Active Consumers decreased to 6.4 million in Q1 2025 from 6.7 million in Q1 2024[106] - Subscription plans totaled 680,000 as of March 31, 2025, down from 778,000 a year earlier[108] - The company expects a year-over-year decline in Monthly Active Consumers in the near term due to changes in retail pharmacy reimbursement models[105] Cash Flow and Financial Position - Cash and cash equivalents as of March 31, 2025, were $301.0 million, with $91.7 million available under a revolving credit facility[135] - Net cash provided by operating activities decreased by $33.2 million year-over-year, totaling $9.41 million in Q1 2025[142] - Net cash used in investing activities increased by $31.3 million year-over-year, primarily due to a $30.0 million increase in cash paid for business acquisition[143] - General and administrative expenses decreased by $11.5 million, or 28%, year-over-year, totaling $29.63 million in Q1 2025[130] Strategic Outlook - Revenue from Rite Aid is forecasted to be less than 5% of total revenue in 2025 due to store closures and bankruptcy proceedings[100] - The company aims to build a leading consumer-focused digital healthcare platform in the U.S. to address rising copays on prescription medications[99] - The company anticipates that prescription volume will migrate to other in-network pharmacies despite the adverse impact from retail pharmacy changes[100] - Adjusted Revenue for Q1 2025 was equal to reported revenue, excluding client contract termination costs[110]